The primary objective of this study was to evaluate the pharmacokinetics (PK) of THC, 11-OH-THC and CBD following a single inhaled dose of PPP001 administered by vaporization. The secondary objective of this study was to determine the safety and tolerability of THC and CBD after a single inhaled dose of PPP001 administered by vaporization in healthy volunteers.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Assessment of adverse events [Safety and Tolerability]
Timeframe: over 5 days
Biochemistry test results [Safety and Tolerability]
Timeframe: over 5 days
Temperature [Safety and Tolerability]
Timeframe: over 5 days
Pulse rate [Safety and Tolerability]
Timeframe: over 5 days
Blood pressure [Safety and Tolerability]
Timeframe: over 5 days
Clinically significant ECG abnormalities [Safety and Tolerability]
Timeframe: over 5 days
Plasma concentrations of delta-9-tetrahydrocannabinol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days
Plasma concentrations of 11-OH-delta-9-tetrahydrocannabinol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days
Plasma concentrations of cannabidiol produced by PPP001 were determined. (pharmacokinetics)
Timeframe: over 5 days